AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35766913 — intervention group
Group type: EXPERIMENTAL
Intervention: MoveStrong program (16 exercise physiologist-led sessions and 2 dietitian-led sessions over 8 weeks)
Number of subjects: 44
Study 32409219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis aided awake surgery (HAs)
Number of subjects: 15
Study 32409219 — intervention group
Group type: COMPARATOR
Intervention: Standard awake surgery (SAs)
Number of subjects: 15
Study 36127422 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifocal + atropine
Number of subjects: 35
Study 36127422 — intervention group
Group type: COMPARATOR
Intervention: Atropine only (control)
Number of subjects: 35
Study 32888861 — intervention group
Group type: EXPERIMENTAL
Intervention: 18G blunt-tipped microcannula
Number of subjects: 68
Study 32888861 — intervention group
Group type: COMPARATOR
Intervention: 26G sharp needle
Number of subjects: 68
Study 33274528 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews (2.0 mm diameter and 10 mm length) placed without pre-drilling and loaded immediately after insertion.
Number of subjects: 47
Study 33274528 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrews evaluated after 4 weeks.
Number of subjects: 47
Study 33274528 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal removal torque evaluated at the end of treatment in Group 3.
Number of subjects: 47
Study 35192502 — intervention group
Group type: EXPERIMENTAL
Intervention: Transulnar approach (TUA)
Number of subjects: 700
Study 33373118 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 40
Study 33373118 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 36240495 — intervention group
Group type: EXPERIMENTAL
Intervention: Menstrual health education and proper implementation of the Adolescent Reproductive Sexual Health program
Number of subjects: 0
Study 36240495 — intervention group
Group type: EXPERIMENTAL
Intervention: Free uninterrupted supply of sanitary pads through school and Anganwadi
Number of subjects: 0
Study 36240495 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate toilets for girls
Number of subjects: 0
Study 32412273 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical pumping scheme to suppress leakage errors
Number of subjects: 0
Study 32412273 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 36007597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedosiran
Number of subjects: 35
Study 36007597 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedosiran (PH1 subgroup)
Number of subjects: 35
Study 36007597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 33676294 — intervention group
Group type: EXPERIMENTAL
Intervention: Entrectinib
Number of subjects: 71
Study 33676294 — intervention group
Group type: COMPARATOR
Intervention: Prior therapy
Number of subjects: 71
Study 33035459 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat 800 mg orally twice per day in continuous 28-day cycles
Number of subjects: 62
Study 37222977 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid arch bar (HAB)
Number of subjects: 44
Study 37222977 — intervention group
Group type: COMPARATOR
Intervention: Erich arch bar (EAB)
Number of subjects: 44
Study 34315379 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions of Daily Care (IDC)
Number of subjects: 40
Study 34315379 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 40
Study 34889140 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) measurement
Number of subjects: 228
Study 34889140 — intervention group
Group type: COMPARATOR
Intervention: Psychological stress measures (caregiver burden and caregiver reactions)
Number of subjects: 228
Study 32249609 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral isometric handgrip training (4×2 min at 25% of maximal voluntary contraction, 3 days/week for 8 weeks)
Number of subjects: 20
Study 32249609 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 32249609 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral isometric handgrip training
Number of subjects: 20
Study 33845867 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX)
Number of subjects: 171
Study 33845867 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib (FOS)
Number of subjects: 171
Study 33845867 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 171
Study 32065415 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral controlled-release ketamine tablets (60, 120, or 240 mg)
Number of subjects: 24
Study 32065415 — intervention group
Group type: COMPARATOR
Intervention: Injected ketamine
Number of subjects: 24
Study 32065415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 34731198 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage by a nurse using a new extension to the Manchester Triage System during intervention weekends.
Number of subjects: 8538
Study 34731198 — intervention group
Group type: COMPARATOR
Intervention: Control group where all patients remained at the ED during control weekends.
Number of subjects: 8538
Study 34731198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group assignment to GPC.
Number of subjects: 8538
Study 34731198 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance of the study tool during intervention weekends.
Number of subjects: 8538
Study 33086137 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating on Zirconomer (ZR)
Number of subjects: 60
Study 33086137 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating on Equia Forte (EQ)
Number of subjects: 60
Study 33086137 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin coating on Riva (RV)
Number of subjects: 60
Study 33086137 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Zirconomer (ZR)
Number of subjects: 60
Study 33086137 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Equia Forte (EQ)
Number of subjects: 60
Study 33086137 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Riva (RV)
Number of subjects: 60
Study 32682556 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine 6 μg ml−1
Number of subjects: 668
Study 32682556 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100 μg ml−1
Number of subjects: 668
Study 35143325 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Oral Anticoagulants (DOACs)
Number of subjects: 845
Study 35143325 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 845
Study 33164784 — intervention group
Group type: EXPERIMENTAL
Intervention: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fasted condition
Number of subjects: 20
Study 33164784 — intervention group
Group type: COMPARATOR
Intervention: Garcinia cambogia extract (GCE)/(−) – hydroxycitric acid (HCA) 1500/750 mg under fed condition after a high calorie breakfast (600 calories)
Number of subjects: 20
Study 32833285 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-guided therapy (bismuth-containing quadruple therapy guided by antimicrobial susceptibility testing)
Number of subjects: 356
Study 32833285 — intervention group
Group type: COMPARATOR
Intervention: PMH-guided therapy (personal medication history-guided therapy)
Number of subjects: 356
Study 32833285 — intervention group
Group type: EXPERIMENTAL
Intervention: AST clarithromycin regimen
Number of subjects: 356
Study 32833285 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin regimen
Number of subjects: 356
Study 32833285 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone-containing regimen
Number of subjects: 356
Study 32833285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AST and PMH therapies
Number of subjects: 356
Study 36100890 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine screening and management of depression in the intervention group.
Number of subjects: 370
Study 36100890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no routine screening and management of depression).
Number of subjects: 370
Study 34058023 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma transfusion (10–15 cc/kg)
Number of subjects: 57
Study 34058023 — intervention group
Group type: COMPARATOR
Intervention: No transfusion
Number of subjects: 57
Study 33046136 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4-mg
Number of subjects: 240
Study 33046136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 35960344 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannulated screws
Number of subjects: 28
Study 35960344 — intervention group
Group type: COMPARATOR
Intervention: K-wires
Number of subjects: 28
Study 32933625 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of recombinant human interferon α1b in addition to intravenous drip of acyclovir (observation group)
Number of subjects: 182
Study 32933625 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drip of acyclovir (control group)
Number of subjects: 182
Study 34364099 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep SAPB
Number of subjects: 64
Study 34364099 — intervention group
Group type: COMPARATOR
Intervention: Superficial SAPB
Number of subjects: 64
Study 33258654 — intervention group
Group type: EXPERIMENTAL
Intervention: Local random measurements on the state, followed by postprocessing using the classical shadows framework
Number of subjects: 0
Study 33258654 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing experimental data from Brydges et al. (2019)
Number of subjects: 0
Study 33463583 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐DAVS
Number of subjects: 68
Study 33463583 — intervention group
Group type: COMPARATOR
Intervention: CAM
Number of subjects: 68
Study 32510158 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch type 3 (RS‐WM; 22 or 26 g/d for females and males, respectively)
Number of subjects: 19
Study 32510158 — intervention group
Group type: COMPARATOR
Intervention: No resistant starch (C‐WM)
Number of subjects: 19
Study 36344002 — intervention group
Group type: EXPERIMENTAL
Intervention: tele-exercise rehabilitation for 6 months
Number of subjects: 794
Study 36344002 — intervention group
Group type: COMPARATOR
Intervention: routine remote rehabilitation (control group)
Number of subjects: 794
Study 33742207 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU monthly)
Number of subjects: 5108
Study 33742207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5108
Study 32236818 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa 500 mg once daily
Number of subjects: 140
Study 32236818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 34873652 — intervention group
Group type: EXPERIMENTAL
Intervention: PoLaRS training system
Number of subjects: 38
Study 34873652 — intervention group
Group type: COMPARATOR
Intervention: dVSS (Intuitive Surgical's da Vinci Skills Simulator)
Number of subjects: 38
Study 36079744 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-fortified, milk-derived protein matrix (MBPM)
Number of subjects: 0
Study 33878556 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsule (PC; n = 25) containing probiotic strains
Number of subjects: 45
Study 33878556 — intervention group
Group type: COMPARATOR
Intervention: Control capsule (CC; n = 20) containing a matching placebo
Number of subjects: 45
Study 35555136 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (300 mg/70 mL) consumed acutely and for 7 days
Number of subjects: 15
Study 32566096 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir (SOF) and Ribavirin (RBV) with Black Cumin (BLC) and Ascorbate (ASC)
Number of subjects: 30
Study 32566096 — intervention group
Group type: COMPARATOR
Intervention: Sofosbuvir (SOF) and Ribavirin (RBV)
Number of subjects: 30
Study 35599917 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 carnosine and anserine ingestion 60 minutes before performance (Study A)
Number of subjects: 26
Study 35599917 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 carnosine and anserine (Study B)
Number of subjects: 26
Study 35599917 — intervention group
Group type: COMPARATOR
Intervention: 30 mg.kg‐1 carnosine and anserine, placebo, or antihistamines (Study C)
Number of subjects: 26
Study 33232340 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of anatomical side markers (ASMs) on radiographs
Number of subjects: 421
Study 33232340 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with radiographers
Number of subjects: 421
Study 34923180 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus TACE
Number of subjects: 92
Study 34923180 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 92
Study 34597179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cops & Rubbers game
Number of subjects: 70
Study 34597179 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet
Number of subjects: 70
Study 35637842 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate combined with Entresto
Number of subjects: 120
Study 35637842 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate
Number of subjects: 120
Study 34052580 — intervention group
Group type: EXPERIMENTAL
Intervention: 9‐week, interactive, family‐based intervention
Number of subjects: 52
Study 34052580 — intervention group
Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 52
Study 34128429 — intervention group
Group type: COMPARATOR
Intervention: Reference case (male, lung cancer, stage I, no symptoms)
Number of subjects: 255494
Study 32478660 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth app prescription intervention
Number of subjects: 36
Study 32319168 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin 5 mg
Number of subjects: 207
Study 32319168 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg
Number of subjects: 207
Study 32319168 — intervention group
Group type: EXPERIMENTAL
Intervention: Evogliptin/evogliptin group
Number of subjects: 207
Study 32319168 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 207
Study 36414647 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivy leaves dry extract EA 575
Number of subjects: 390
Study 36414647 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 34690120 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tDCS (1.5 mA, 20 min, 12 sessions) + Mindfulness-based substance abuse treatment (MBSAT)
Number of subjects: 80
Study 34690120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based substance abuse treatment (MBSAT)
Number of subjects: 80
Study 34690120 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (1.5 mA, 20 min, 12 sessions)
Number of subjects: 80
Study 34690120 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 80
Study 35634610 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-A: Capsule Amoxicillin 1 gm; Tablet Clarithromycin 500 mg; Capsule Omeprazole 20 mg, twice daily for two weeks.
Number of subjects: 179
Study 35634610 — intervention group
Group type: COMPARATOR
Intervention: Group-B: Capsule Amoxicillin 1 gm; Tablet Vonoprazan 20 mg, twice daily for two weeks.
Number of subjects: 179
Study 33048829 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Diabetic Foot Personal Care System (m-DAKBAS) app used for 6 months
Number of subjects: 88
Study 33048829 — intervention group
Group type: COMPARATOR
Intervention: Control group (verbal-only instruction)
Number of subjects: 88
Study 35971757 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive risk label ('very low risk')
Number of subjects: 8998
Study 35971757 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison to motor-vehicle mortality
Number of subjects: 8998
Study 35971757 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both framing strategies
Number of subjects: 8998
Study 33517953 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 92
Study 33517953 — intervention group
Group type: COMPARATOR
Intervention: Bag-Valve-Mask (BVM)
Number of subjects: 92
Study 32874103 — intervention group
Group type: EXPERIMENTAL
Intervention: HIITrun
Number of subjects: 14
Study 32874103 — intervention group
Group type: EXPERIMENTAL
Intervention: HIITbike
Number of subjects: 14
Study 35908558 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab plus IBI305 plus pemetrexed and cisplatin
Number of subjects: 444
Study 35908558 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone (pemetrexed and cisplatin)
Number of subjects: 444
Study 33765688 — intervention group
Group type: EXPERIMENTAL
Intervention: Traumeel S
Number of subjects: 17
Study 33765688 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 17
Study 36458455 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual transcranial direct current stimulation (tDCS)
Number of subjects: 66
Study 36458455 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (tDCS)
Number of subjects: 66
Study 33011737 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA esterified in monoacylglycerides (MAG)
Number of subjects: 20
Study 33011737 — intervention group
Group type: COMPARATOR
Intervention: n-3 FA esterified in ethyl ester (EE)
Number of subjects: 20
Study 34033804 — intervention group
Group type: EXPERIMENTAL
Intervention: IV iron 1,000 mg
Number of subjects: 1000
Study 34033804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 33070057 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Oriented Recovery Enhancement intervention (8 weeks)
Number of subjects: 107
Study 33070057 — intervention group
Group type: COMPARATOR
Intervention: Neutral cue exposure
Number of subjects: 107
Study 33070057 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's own prescribed opioid exposure
Number of subjects: 107
Study 33070057 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 107
Study 35510389 — intervention group
Group type: EXPERIMENTAL
Intervention: Flying intervention team care
Number of subjects: 157
Study 35510389 — intervention group
Group type: COMPARATOR
Intervention: Patient interhospital transfer
Number of subjects: 157
Study 32441458 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 8
Study 32441458 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 8
Study 32441458 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 8
Study 33992228 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training (35 Hz) twice a week for 12 weeks
Number of subjects: 12
Study 33992228 — intervention group
Group type: COMPARATOR
Intervention: Sham Group training
Number of subjects: 12
Study 32112920 — intervention group
Group type: EXPERIMENTAL
Intervention: Abacus-based mental calculation (AMC) training
Number of subjects: 36
Study 32112920 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 33617953 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 154
Study 33617953 — intervention group
Group type: COMPARATOR
Intervention: No targeted therapy (Control)
Number of subjects: 154
Study 35410496 — intervention group
Group type: EXPERIMENTAL
Intervention: AKL-T03
Number of subjects: 37
Study 35410496 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 37
Study 32593117 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-lapse imaging (TLI) technologies
Number of subjects: 25
Study 34324016 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 150
Study 34324016 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy-guided injection
Number of subjects: 150
Study 34324016 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided injection
Number of subjects: 150
Study 33000490 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pyrotinib in combination with epirubicin and cyclophosphamide followed by docetaxel and trastuzumab (P + EC-TH)
Number of subjects: 20
Study 33290317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular discomfort scores (mean 4.28 on an 11-point scale)
Number of subjects: 535
Study 33290317 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular Surface Disease Index scores
Number of subjects: 535
Study 33290317 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of interference with activities of daily living
Number of subjects: 535
Study 32241670 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity (HF) simulation model
Number of subjects: 107
Study 32241670 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity (LF) simulation model
Number of subjects: 107
Study 35723150 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based follow-up on top of a home-based joint protection education programme
Number of subjects: 0
Study 35723150 — intervention group
Group type: COMPARATOR
Intervention: Home-based joint protection education alone
Number of subjects: 0
Study 33735590 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg HB vaccine
Number of subjects: 428
Study 35959685 — intervention group
Group type: EXPERIMENTAL
Intervention: App-assisted home blood pressure monitoring (HBPM)
Number of subjects: 113
Study 35959685 — intervention group
Group type: COMPARATOR
Intervention: Automated office blood pressure (OBP)
Number of subjects: 113
Study 35959685 — intervention group
Group type: COMPARATOR
Intervention: 24-hour ambulatory blood pressure monitoring (ABPM)
Number of subjects: 113
Study 35959685 — intervention group
Group type: COMPARATOR
Intervention: Unattended 30-minute blood pressure monitoring
Number of subjects: 113
Study 34120835 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d for females; 15 g/d for males)
Number of subjects: 12
Study 34120835 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (6 g/d for females; 9 g/d for males)
Number of subjects: 12
Study 35367176 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT guidance
Number of subjects: 246
Study 35367176 — intervention group
Group type: COMPARATOR
Intervention: Angiographic guidance
Number of subjects: 246
Study 34172301 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Sgarbossa Criteria (MSC)
Number of subjects: 251